CTS Corp Q2 2026: Sales Climb 7%, Margins Reach Record, Guidance Lifted
CTS sits 78% above its 52-week low of $36.025.
Summary
CTS Corp posted Q2 2026 sales of $144.8M (+7% YoY) and record gross margins of 41.5%, while raising full-year guidance. Net earnings were $19.2M, impacted by a higher tax rate.
Key Events · Earnings and Guidance · CTS
-
Q2 Revenue and Margin Beat
Net sales rose 7% to $144.8 million, driven by 14.6% growth in diversified end markets. Gross margin hit a record 41.5%, up from 38.7% a year ago, reflecting favorable mix and operational improvements.
-
Full-Year Guidance Raised
CTS raised FY 2026 revenue guidance to $565–$585 million, up from prior outlook, citing strong demand in medical and industrial markets.
-
Tax Rate Headwind
Effective tax rate jumped to 27.0% from 19.4% due to valuation allowances against certain tax credits, limiting net earnings growth to 3.4% despite strong operating performance.
-
Strong Balance Sheet and Buybacks
Cash and equivalents stood at $107.5 million with $243.5 million available under the revolver. The company repurchased $3.5 million in shares during Q2, with $78.3 million remaining under its authorization.
Analysis · CTS · Manufacturing
A strong second quarter saw CTS Corporation lift sales 7% to $144.8 million while gross margins expanded to a record 41.5%. Net earnings edged up to $19.2 million, though a higher tax rate—driven by valuation allowances—tempered the advance. Reflecting confidence in sustained demand across medical and industrial markets, management raised full-year revenue guidance to $565–$585 million. The balance sheet remains sturdy with $107.5 million in cash and ample revolver capacity, and the buyback program continues with $78.3 million remaining. This quarter underscores the growth narrative and operational execution under new CEO Pratik Trivedi.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 29.1% of the 1568 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.60%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CTS was trading at $64.01 on NYSE in the Manufacturing sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $36.03 to $69.55. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.